The given column graph illustrates the amounts of investing money to researches of five large pharmaceutical companies: Novas, Fleming, Biopharm, Avicenna and Pharm in 2012, 2018 and 2022. It is clear from the graph that all the companies had the trend for the increasing their investment.
The ladder in increasing investment is “Novas” spending more than 50 $bn in 2022. It is interesting to note that “Fleming” and “Novas” had particular the same amount in 2018, although the Fleming’s investment was higher in 2012 that in Novas.
In addition, “Biopharm”, “Avicenna” and “Pharm” had similar statistics: Biopharm’s investment is approximately 25$bn while Avicenna’s and Pharm’s ones are a little less that this amount in 2022. In 2018 was the opposite trend as Pharm’s and Fleming’s indicator were almost similar while Biopharm took the last place.
It is important to mention that Biopharm almost did not make putting money into researching in 2012. At the same time, almost all companies had small statistics except Pharm that had around 10$bn in 2012.
Overall, the indicators of all companies extremely went up over these 3 reporting years.